Genstruct announces new collaboration with Pfizer in drug safety
CAMBRIDGE, Mass., February 20, 2008 /PRNewswire/ — Genstruct Inc., a systems biology company focused on identifying molecular mechanisms, networks and biomarkers to better understand large scale biology announced today that it has entered into a Master Research Agreement with Pfizer designed to cover current and future collaborations. The first collaboration under this new agreement is in the area of preclinical drug safety, focusing initially on a systems biology analysis of underlying mechanisms of drug-induced liver injury.
© 2021 Pappas Capital, LLC. ALL RIGHTS RESERVED.